List of Excipients in Branded Drug VTAMA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Organon LLC	VTAMA	tapinarof	81672-5051	BENZOIC ACID	2038-11-13
Organon LLC	VTAMA	tapinarof	81672-5051	BUTYLATED HYDROXYTOLUENE	2038-11-13
Organon LLC	VTAMA	tapinarof	81672-5051	CITRIC ACID MONOHYDRATE	2038-11-13
Organon LLC	VTAMA	tapinarof	81672-5051	DIETHYLENE GLYCOL MONOETHYL ETHER	2038-11-13
Organon LLC	VTAMA	tapinarof	81672-5051	EDETATE DISODIUM	2038-11-13
Organon LLC	VTAMA	tapinarof	81672-5051	MEDIUM-CHAIN TRIGLYCERIDES	2038-11-13
Organon LLC	VTAMA	tapinarof	81672-5051	POLAWAX POLYSORBATE	2038-11-13

VTAMA Excipient Strategy and Commercial Opportunities in Topical Tapinarof

Last updated: August 27, 2026

VTAMA is a nonsteroidal tapinarof 1% cream whose commercial value depends partly on its emulsion vehicle. The formulation combines a penetration-oriented solvent system with fatty alcohols, emollients, surfactants, humectants, and mineral oil. This supports once-daily topical delivery for plaque psoriasis and atopic dermatitis, but it also creates opportunities for differentiated products based on tolerability, packaging, pediatric use, preservation, and application convenience.

The strongest excipient opportunities are unlikely to come from simple substitution of one inactive ingredient. They are more likely to arise from a demonstrably improved vehicle, including lower-irritancy systems, preservative-reduced products, spray or foam delivery, pediatric-friendly packaging, and formulations optimized for sensitive or intertriginous skin.

What is VTAMA and how does its formulation work?

VTAMA contains tapinarof 1% in a topical cream vehicle. Tapinarof is a small-molecule aryl hydrocarbon receptor agonist used for inflammatory dermatologic conditions. The FDA approved VTAMA for plaque psoriasis in adults in 2022 and later expanded use to pediatric patients. The product has also been developed and approved for atopic dermatitis in patients aged 2 years and older, according to subsequent FDA labeling and company disclosures.[1,2]

The formulation is designed to:

• Dissolve or disperse tapinarof sufficiently for uniform dosing.
• Support movement of the active ingredient into the stratum corneum.
• Maintain spreadability over large body surfaces.
• Provide emollience without relying on topical corticosteroids.
• Permit once-daily use.
• Remain suitable for chronic treatment.

The commercial distinction is important. VTAMA competes against topical corticosteroids, topical calcineurin inhibitors, PDE-4 inhibitors, and other nonsteroidal dermatology products. Vehicle tolerability can affect adherence, particularly in atopic dermatitis, where barrier impairment and stinging are common.

What excipients are used in VTAMA cream?

The FDA prescribing information identifies a multi-component cream vehicle. Public labeling has identified the following inactive ingredients:

Excipient	Likely formulation function	Commercial or technical relevance
Benzyl alcohol	Preservative and solvent	Can create pediatric, irritation, sensitization, and labeling considerations
Cetostearyl alcohol	Consistency agent and emollient	Improves cream structure and skin feel
Cetyl alcohol	Emollient and viscosity modifier	Supports semisolid texture
Diethylene glycol monoethyl ether	Solvent and penetration-enhancing vehicle component	May improve tapinarof solubilization and dermal delivery
Glycerin	Humectant	Supports moisturization and may improve barrier feel
Glyceryl stearate	Emulsifier and emollient	Contributes to oil-in-water cream architecture
Isopropyl myristate	Emollient and penetration enhancer	Improves spreadability but can affect irritation and comedogenicity profiles
Mineral oil	Occlusive emollient	Supports barrier feel and reduces transepidermal water loss
Polysorbate 60	Surfactant and emulsifier	Stabilizes the dispersed phase
Propylene glycol	Solvent and humectant	Supports solubilization but can sting compromised skin
Purified water	Continuous aqueous phase	Main vehicle component
Sodium hydroxide or pH-adjusting components	pH control	Supports stability and skin compatibility

The exact composition, concentration ranges, manufacturing controls, and process parameters may be protected in formulation or manufacturing filings even when the ingredient names appear in the FDA label. FDA labeling generally discloses inactive ingredient identity, not the full commercial formulation design space.[1]

Why is the VTAMA solvent and penetration system commercially important?

Tapinarof must reach viable epidermal and dermal targets while maintaining acceptable skin tolerability. Diethylene glycol monoethyl ether, also known as Transcutol-type solvent, is particularly relevant because it can function as both a solvent and a dermal delivery aid. Propylene glycol and isopropyl myristate may contribute to solubilization, spreading, and partitioning into the skin.

This combination creates three commercial advantages:

1. It can support a relatively low active concentration of 1%.
2. It may reduce the need for a highly greasy ointment.
3. It permits broad-area application in psoriasis and atopic dermatitis.

The same strategy creates formulation risks. Penetration-enhancing solvents can increase stinging or irritation in patients with fissured, inflamed, or barrier-deficient skin. A competing formulation with comparable exposure and a lower sensory burden could obtain meaningful market share without changing the active ingredient.

What excipient strategies could improve VTAMA?

Lower-irritancy vehicles for atopic dermatitis

A lower-sting formulation is the clearest opportunity. Potential approaches include:

• Reducing or replacing propylene glycol.
• Evaluating alternatives to benzyl alcohol as a preservative.
• Lowering the concentration of penetration enhancers.
• Using a buffered system closer to physiologic skin pH.
• Incorporating barrier-supportive lipids or ceramide systems.
• Reducing surfactant load while maintaining emulsion stability.

Any reformulation would need to preserve tapinarof release, skin penetration, physical stability, microbial protection, and clinical performance. An apparently gentler product could lose efficacy if the active becomes less available at the target site.

Preservative-reduced or preservative-free packaging

Benzyl alcohol is commercially useful but may be viewed as a limitation in pediatric and sensitive-skin populations. A preservative-reduced or preservative-free VTAMA presentation could use:

• Airless pumps.
• One-way valve tubes.
• Single-use sachets.
• Unit-dose blister packs.
• Low-water or anhydrous systems.

Packaging-based preservation is commercially attractive because it can reduce preservative exposure without requiring a new active ingredient. The principal technical barriers are microbial challenge testing, compatibility with the container closure, dose uniformity, and product shelf life.

Foam, spray, and gel delivery

A cream is effective for plaques and eczematous lesions but may be less convenient for scalp, hairy areas, or large body surfaces. Alternative dosage forms could target specific use cases:

Dosage form	Target opportunity	Main formulation challenge
Foam	Scalp and hair-bearing areas	Maintaining tapinarof solubility and aerosol or pump stability
Spray	Large-area psoriasis and difficult-to-reach sites	Dose uniformity and inhalation or ocular exposure control
Gel	Oily or hairy areas	Avoiding alcohol-related sting and drying
Lotion	Large surface area and pediatric use	Physical stability and adequate skin delivery
Ointment	Severe xerosis or fissured plaques	Greasiness and lower patient acceptability
Hydrogel	Acute inflammation and cooling sensation	Tapinarof solubilization and preservative control
Anhydrous balm	Barrier-compromised skin	Active distribution and user preference

A foam or spray would probably require a new formulation development program rather than a simple line extension. It could also require a separate FDA regulatory submission, depending on the extent of formulation and delivery changes.

What commercial opportunities exist for VTAMA excipients?

Pediatric dermatology

Pediatric labeling expands the addressable population but increases scrutiny of excipient exposure. Children with atopic dermatitis often have extensive barrier disruption and repeated treatment cycles. A pediatric-optimized product could emphasize:

• Lower stinging.
• Reduced fragrance and allergen burden.
• Easy dispensing.
• Precise dosing.
• Low transfer to clothing.
• Compatibility with caregiver application.

A lower-volume pump or metered-dose package could support more consistent dosing than a tube. Unit-dose packaging could also reduce contamination in households where multiple family members use topical products.

Atopic dermatitis positioning

Atopic dermatitis offers a larger recurring-treatment market than plaque psoriasis but imposes greater demands on tolerability. A vehicle with a non-greasy finish, low sting, and barrier-supportive profile could compete with topical PDE-4 inhibitors and corticosteroid-sparing therapies.

The commercial opportunity is strongest in:

• Face and neck treatment.
• Flexural areas.
• Pediatric patients.
• Maintenance treatment.
• Patients avoiding topical steroids.
• Patients who discontinue products because of burning or residue.

Scalp and intertriginous disease

Creams perform less well in hair-bearing areas and may be difficult to apply under clothing or in skin folds. A scalp foam, low-residue lotion, or pump spray could expand use beyond standard plaque application.

The technical target is not simply lower viscosity. The formulation must deliver a reproducible tapinarof dose while limiting run-off, ocular exposure, flammability, and transfer to hair or textiles.

International licensing and regional formulation partnerships

A regional partner could add value through:

• Local manufacturing of the cream.
• Alternate tube and pump presentations.
• Country-specific excipient sourcing.
• Formulation adaptation for hot and humid climates.
• Lower-cost packaging.
• Pediatric and hospital-channel presentations.

The most practical licensing structure would likely involve rights to a defined dosage form or geography rather than a broad license to the underlying tapinarof platform. Manufacturing partners with topical semi-solid expertise could reduce cost of goods and improve supply resilience.

How does VTAMA compare with competing topical products?

Product	Active	Class	Vehicle opportunity relative to VTAMA
VTAMA	Tapinarof	Aryl hydrocarbon receptor agonist	Cream vehicle supports broad-area use; foam or lotion could expand convenience
Zoryve cream/foam	Roflumilast	PDE-4 inhibitor	Foam format gives an advantage for scalp and hair-bearing areas
Eucrisa	Crisaborole	PDE-4 inhibitor	Known application-site burning creates an opening for lower-sting vehicles
Protopic/Elidel	Tacrolimus/pimecrolimus	Calcineurin inhibitors	Ointment and cream sensory profiles can limit acceptance
Topical corticosteroids	Various	Anti-inflammatory steroids	Strong efficacy, but long-term safety concerns support steroid-sparing products
Opzelura	Ruxolitinib	JAK inhibitor	Cream vehicle competes in atopic dermatitis; regulatory safety labeling affects positioning

VTAMA’s main vehicle advantage is broad-area cream usability. Its main formulation vulnerability is the potential for excipient-related stinging or irritation in patients with damaged skin. Zoryve’s foam demonstrates that dosage form can create a differentiated commercial segment even when the underlying topical therapy is already available as a cream.

What FDA regulatory issues affect VTAMA reformulations?

A reformulated tapinarof product could follow different regulatory pathways depending on the change:

• A new strength or materially different dosage form may require a supplemental or standalone application.
• A change in excipient concentration may require comparative quality, stability, and possibly clinical data.
• A new route or delivery system could require expanded nonclinical and clinical assessment.
• A preservative-free presentation would require robust microbiological and container-closure data.
• A pediatric-specific product would require dosing and safety support appropriate to the target age group.

The FDA-approved product’s inactive ingredients are listed for labeling and safety purposes, but that disclosure does not establish that every ingredient combination is therapeutically equivalent. For a generic or follow-on product, formulation differences can affect release, absorption into skin, local tolerability, and equivalence requirements.

What patent and exclusivity issues affect excipient opportunities?

VTAMA’s intellectual-property position may include separate protection for:

• Tapinarof composition of matter.
• Topical compositions containing tapinarof.
• Specific concentration ranges.
• Treatment methods for psoriasis or atopic dermatitis.
• Manufacturing and purification processes.
• Physical forms, stability, or delivery systems.

An excipient strategy can create a distinct patent position when it claims a defined combination, concentration range, particle or phase structure, process condition, or performance parameter. A generic excipient substitution that merely uses conventional ingredients is less likely to create durable exclusivity.

The Orange Book status, listed patents, pediatric exclusivity, and any approved use codes should be reviewed before a commercial launch or Paragraph IV strategy. A new formulation may face separate patent risk even if it avoids the formulation used in the branded product. Conversely, a branded company may use a new dosage form to extend market protection if the claims cover a commercially meaningful delivery system.

Publicly available product information confirms FDA approval and the labeled inactive ingredients. It does not, by itself, establish the full scope or enforceability of VTAMA formulation patents. Patent claims must be reviewed individually for claim construction, expiration, terminal disclaimers, prosecution history, and Orange Book listing status.

What generic entry risks exist for VTAMA?

Generic competition could emerge through an ANDA for tapinarof cream 1%, subject to the applicable FDA requirements. The principal barriers are:

1. Demonstrating pharmaceutical equivalence.
2. Matching or adequately comparing topical performance.
3. Establishing bioequivalence under the FDA’s product-specific framework.
4. Replicating or bypassing relevant formulation patents.
5. Producing a stable, microbiologically controlled cream at competitive cost.
6. Meeting container-closure and dose-uniformity requirements.

A generic entrant may attempt to retain the core excipient architecture while changing noncritical concentrations or replaceable ingredients. That approach can reduce development risk but may leave the product exposed to formulation patent claims.

A materially different vehicle, such as a foam or spray, is more likely to compete as an alternative product than as a conventional generic. Its commercial success would depend on clinical convenience, reimbursement, and whether the new dosage form solves a recognized limitation of the cream.

How strong is the commercial opportunity for VTAMA excipient innovation?

The opportunity is moderate to strong in differentiated topical delivery, but weaker in commodity excipient substitution.

Opportunity	Market value	Development complexity	Patent potential
Lower-sting cream	High	Moderate to high	Moderate
Preservative-free pump	Moderate to high	Moderate	Moderate
Pediatric metered-dose package	Moderate	Moderate	Moderate
Scalp foam	High	High	High
Large-area spray	Moderate to high	High	High
Low-cost generic cream	High volume, lower margin	Moderate	Low to moderate
Barrier-lipid cream	Moderate	High	Moderate to high
Climate-stable formulation	Moderate internationally	Moderate	Moderate

The most defensible strategy is a platform approach: retain tapinarof’s established therapeutic profile while developing separate vehicles for sensitive skin, scalp disease, pediatric use, and large-area application. Commercial value would come from improved adherence and access rather than from excipient novelty alone.

Key Takeaways

• VTAMA uses a complex cream vehicle combining solvents, penetration-oriented excipients, emollients, emulsifiers, humectants, and preservatives.
• The main formulation opportunity is a lower-sting, sensitive-skin vehicle for atopic dermatitis and pediatric use.
• Preservative-reduced packaging could improve positioning without requiring a completely new active formulation.
• Foam, spray, lotion, and gel presentations could expand VTAMA into scalp, hair-bearing, intertriginous, and large-area applications.
• Excipient substitution alone is unlikely to create strong commercial differentiation unless it improves tolerability, delivery, stability, or adherence.
• Formulation patents may cover concentration ranges, vehicle architecture, manufacturing processes, or dosage forms beyond the ingredient list in the FDA label.
• Generic entry risk depends on Orange Book listings, applicable exclusivity, bioequivalence requirements, and the scope of formulation claims.
• The highest-value commercial strategy is a differentiated topical platform rather than a single reformulated cream.

FAQs About VTAMA Excipient Strategy

Can benzyl alcohol be removed from VTAMA?

Potentially, but removal would require a new preservation and stability strategy. An airless pump, unit-dose package, lower-water formulation, or alternative preservative system could reduce reliance on benzyl alcohol.

Which VTAMA excipient is most relevant to skin penetration?

Diethylene glycol monoethyl ether is the most prominent penetration-oriented solvent in the labeled vehicle. Propylene glycol and isopropyl myristate may also contribute to solubilization and dermal partitioning.

Could a VTAMA foam compete with Zoryve foam?

Yes. A tapinarof foam could target scalp and hair-bearing areas where a cream is less convenient. It would require demonstration of formulation stability, dose delivery, tolerability, and appropriate FDA regulatory support.

Is a preservative-free VTAMA product commercially attractive?

Yes, particularly for pediatric atopic dermatitis and patients with sensitive skin. The principal hurdles are microbial control, packaging performance, shelf life, and cost.

Can a company launch a generic VTAMA by changing the excipients?

Changing excipients does not eliminate regulatory or patent risk. The product would still need to meet FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and applicable patent certifications.

References

1. U.S. Food and Drug Administration. (2022). VTAMA (tapinarof) cream, 1%: Prescribing information. FDA.
2. Dermavant Sciences Ltd. (2024). VTAMA clinical and regulatory updates for plaque psoriasis and atopic dermatitis. Dermavant Sciences.
3. U.S. Food and Drug Administration. (2024). Drugs@FDA: VTAMA application and labeling materials. FDA.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
5. National Library of Medicine. (2024). DailyMed: VTAMA tapinarof cream, 1%. U.S. National Library of Medicine.